8-K: Arcus Biosciences Reports Strong Gastric Cancer Trial Data

Arcus Biosciences announced positive overall survival and efficacy results from its Phase 2 EDGE-Gastric study for advanced gastric and esophageal adenocarcinoma.

Summary

• Arcus Biosciences reported the first overall survival (OS) results from Arm A1 of its Phase 2 EDGE-Gastric study.
• The study evaluated domvanalimab plus zimberelimab and chemotherapy in 41 patients with locally advanced unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.
• At a data cutoff of March 3, 2025, with a median follow-up of 26.4 months, the median overall survival (OS) was 26.7 months (90% CI: 18.4, NE).
• The 24-month OS rate was 50.2% (90% CI: 36.3, 62.6).
• Median progression-free survival (PFS) was 12.9 months (90% CI: 9.8, 14.6), with a 24-month PFS rate of 25.9% (90% CI: 14.8, 38.5).
• The confirmed overall response rate (ORR) per RECIST v1.1 was 59% (24 patients) (90% CI: 45%, 72%).
• Efficacy was observed across all PD-L1 subgroups, including PD-L1 Positive (TAP ≥1%) and PD-L1 High (TAP ≥5%).
• The safety profile was generally well tolerated and consistent with anti-PD-1 plus chemotherapy, with no unexpected safety signals.

Sentiment

Score: 9

Explanation: The clinical trial results demonstrate strong efficacy across multiple endpoints (OS, PFS, ORR) in a challenging cancer type, with a manageable safety profile. This is a highly positive development for the company's pipeline.

Positives

• Median overall survival of 26.7 months demonstrates sustained efficacy with longer follow-up in a difficult-to-treat patient population.
• A 24-month overall survival rate of 50.2% indicates a significant proportion of patients are surviving long-term.
• Median progression-free survival of 12.9 months suggests effective disease control.
• A high confirmed overall response rate of 59% shows a substantial number of patients experienced tumor shrinkage.
• Efficacy was observed across all PD-L1 subgroups, suggesting broad applicability of the treatment.
• The safety profile was consistent with known anti-PD-1 plus chemotherapy regimens, with no unexpected safety signals.

Negatives

• Immune-mediated treatment-emergent adverse events (TEAEs) related to domvanalimab and/or zimberelimab occurred in 9 patients (22%).
• Infusion-related reactions occurred in 3 patients (7%).

Risks

• Patients experienced immune-mediated treatment-emergent adverse events (TEAEs) related to the study drugs (22% of patients).
• Infusion-related reactions occurred in some patients (7% of patients).

Future Outlook

The filing provides factual clinical trial results and does not include any forward-looking statements, guidance, or future projections regarding regulatory submissions, commercialization, or financial performance.

Management Comments

• The company duly caused this report to be signed on its behalf by Terry Rosen, Ph.D., Chief Executive Officer, indicating the official release of these clinical trial results.

Industry Context

The results are significant in the oncology sector, particularly for the treatment of advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma, which are aggressive cancers with high unmet medical needs. The combination of an anti-TIGIT antibody (domvanalimab), an anti-PD-1 antibody (zimberelimab), and chemotherapy represents a multi-pronged approach to enhance anti-tumor immunity, aligning with broader industry trends towards combination immunotherapies.

Comparison to Industry Standards

• Advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma are aggressive cancers with historically poor prognoses, particularly in the metastatic setting. Standard chemotherapy alone or with PD-1 inhibitors typically yields median overall survival rates ranging from 12-18 months.
• The reported median overall survival of 26.7 months and a 24-month overall survival rate of 50.2% for the domvanalimab plus zimberelimab and chemotherapy regimen represent a significant improvement over these historical benchmarks for this patient population.

Stakeholder Impact

• Shareholders: The positive clinical trial results are likely to be viewed favorably, potentially increasing investor confidence and share price.
• Patients: The data suggests a promising new treatment option for patients suffering from advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma, offering improved survival and disease control.
• Medical Community: The results contribute valuable data to the understanding and treatment of these aggressive cancers, potentially influencing future treatment guidelines and research directions.

Key Dates

Recommendation

The reported Phase 2 EDGE-Gastric study results for domvanalimab plus zimberelimab and chemotherapy are exceptionally strong for advanced gastric and esophageal adenocarcinoma, a disease with high unmet medical need and historically poor outcomes. A median overall survival of 26.7 months and a 24-month OS rate of over 50% represent a significant clinical benefit. These positive efficacy and safety data substantially de-risk the program and enhance the commercial potential of the drug combination, making Arcus Biosciences an attractive investment.

Keywords

Arcus Biosciences, domvanalimab, zimberelimab, EDGE-Gastric, gastric cancer, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma, overall survival, progression-free survival, overall response rate, Phase 2 clinical trial, immunotherapy, PD-L1